Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.
- New Clinical Data on ARO-RAGE Show Continued Dose Response with Single Inhaled Dose of 184 mg Achieving Mean Knockdown of 90% and Max of 95%
- Adipose Delivery Platform Achieved Single Dose. | June 1, 2023
/PRNewswire/ Neuvivo today announced the publication of a paper on its lead candidate drug NP001 for the treatment of ALS in the peer-reviewed journal.